van Driel W J, Tjiong M Y, Hilders C G, Trimbos B J, Fleuren G J
Department of Gynecology, University of Leiden, The Netherlands.
Gynecol Oncol. 1996 Jul;62(1):33-41. doi: 10.1006/gyno.1996.0186.
Immunohistochemical studies have shown that loss of HLA expression is observed in cervical carcinomas but not in premalignant CIN lesions, indicating that downregulation of HLA is linked to tumor progression. The present study was performed to investigate whether the degree of HLA expression in cervical cancer correlates with more advanced disease as defined by histopathological features. Frozen tissue sections from 49 patients with squamous carcinoma of the cervix FIGO stage IB to IIB were stained with HLA class I monomorphic, locus- and allele-specific monoclonal antibodies. Histological data indicative of local disease, i.e., depth of invasion, tumor size, stage, and systemic spread of the disease, such as tumor-positive lymph nodes, were collected by reviewing the histological slides. Univariate analysis revealed that loss of HLA-A locus and A2-allele expression showed a positive, significant correlation with both presence of tumor-positive lymph nodes (P = 0.04 and 0.02, respectively) and the number of lymph nodes involved (both P = 0.04). These results strongly support the idea that, specifically in an immunogenic cancer type such as cervical cancer, tumor cells escape immunosurveillance and gain growth advantage by allele-specific downregulation of the HLA-A2 molecule. In view of the development of immunotherapeutical interventions in cancer, upregulation of HLA class I molecules may prove to be a useful additional tool in the combat against immunogenic tumors.
免疫组织化学研究表明,在宫颈癌中可观察到HLA表达缺失,但在癌前CIN病变中未观察到,这表明HLA下调与肿瘤进展有关。本研究旨在调查宫颈癌中HLA表达程度是否与组织病理学特征所定义的更晚期疾病相关。对49例FIGO分期为IB至IIB期的宫颈鳞状癌患者的冰冻组织切片用HLA I类单态、位点和等位基因特异性单克隆抗体进行染色。通过复查组织学切片收集指示局部疾病的组织学数据,即浸润深度、肿瘤大小、分期以及疾病的全身扩散情况,如肿瘤阳性淋巴结。单因素分析显示,HLA - A位点和A2等位基因表达缺失与肿瘤阳性淋巴结的存在(分别为P = 0.04和0.02)以及受累淋巴结数量(均为P = 0.04)均呈显著正相关。这些结果有力地支持了这样一种观点,即特别是在宫颈癌这种免疫原性癌症类型中,肿瘤细胞通过HLA - A2分子的等位基因特异性下调逃避免疫监视并获得生长优势。鉴于癌症免疫治疗干预措施的发展,上调HLA I类分子可能被证明是对抗免疫原性肿瘤的一种有用的辅助工具。